Glucagon-like peptide-1 receptor agonists and risk of breast cancer
- PMID: 27797789
- DOI: 10.1136/bmj.i5519
Glucagon-like peptide-1 receptor agonists and risk of breast cancer
Similar articles
-
Pharmacogenetics: Genetic approach supports cardiovascular safety of GLP1R agonists.Nat Rev Cardiol. 2016 Aug;13(8):444. doi: 10.1038/nrcardio.2016.100. Epub 2016 Jun 16. Nat Rev Cardiol. 2016. PMID: 27310434 No abstract available.
-
Are basal and glucagon-stimulated C-peptide values predictors of response to GLP-1 receptor agonists in type 2 diabetic patients?Minerva Endocrinol. 2016 Mar;41(1):138-40. Minerva Endocrinol. 2016. PMID: 26878563 No abstract available.
-
Once-weekly glucagon-like peptide 1 receptor agonists.J Pak Med Assoc. 2015 Jul;65(7):796-8. J Pak Med Assoc. 2015. PMID: 26160096 Review.
-
Use of Glucagon-Like-Peptide 1 Receptor Agonists and Risk of Fracture as Compared to Use of Other Anti-hyperglycemic Drugs.Calcif Tissue Int. 2015 Nov;97(5):506-15. doi: 10.1007/s00223-015-0037-y. Epub 2015 Jul 17. Calcif Tissue Int. 2015. PMID: 26184119 Free PMC article.
-
Safety and tolerability of glucagon-like peptide-1 receptor agonists: unresolved and emerging issues.Expert Opin Drug Saf. 2017 Feb;16(2):227-236. doi: 10.1080/14740338.2017.1268598. Epub 2016 Dec 11. Expert Opin Drug Saf. 2017. PMID: 27924636 Review.
Cited by
-
Reversal of tamoxifen resistance by artemisinin in ER+ breast cancer: bioinformatics analysis and experimental validation.Oncol Res. 2024 May 23;32(6):1093-1107. doi: 10.32604/or.2024.047257. eCollection 2024. Oncol Res. 2024. PMID: 38827320 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical